Dermatology and Skin of Color: Clinical Considerations in the US

Skin of color encompasses a broad and clinically distinct patient population in the United States, including individuals of African, Hispanic/Latino, Asian, Native American, Pacific Islander, and Middle Eastern descent. Dermatological conditions in these populations frequently present differently than in lighter-skinned patients, creating well-documented gaps in diagnostic accuracy, treatment selection, and clinical training. This page covers the defining characteristics of skin of color dermatology, the structural and biological factors that drive clinical differences, classification challenges, and the tradeoffs inherent in a field where standardized tools were historically developed on lighter skin tones.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Skin of color dermatology refers to the clinical subspecialty addressing dermatological conditions as they manifest in individuals with higher concentrations of melanin — phototypes IV through VI on the Fitzpatrick Scale, though phototype III is sometimes included depending on the clinical context. The Fitzpatrick Scale, published by Thomas B. Fitzpatrick in 1975 and described in academic literature, classifies skin from Type I (always burns, never tans) through Type VI (never burns, deeply pigmented), and remains the most widely referenced classification framework in clinical and research settings (American Academy of Dermatology, Fitzpatrick Scale reference).

The scope of this subspecialty extends beyond pigment alone. It encompasses hair and scalp biology, keloid and fibrotic wound healing, post-inflammatory hyperpigmentation (PIH), differences in inflammatory response, and the frequency distribution of specific conditions. In the US, populations classified as skin of color — including Black/African American, Hispanic/Latino, Asian American, Native American, and multiracial individuals — represented over 40% of the total US population according to the US Census Bureau's 2020 Decennial Census. As demographic composition shifts, skin of color patients are projected to constitute the numerical majority of the US population by 2045 (US Census Bureau projections).

Conditions with markedly different prevalence or presentation in skin of color populations include acne keloidalis nuchae, traction alopecia, central centrifugal cicatricial alopecia (CCCA), discoid lupus erythematosus (DLE), melasma, and pseudofolliculitis barbae. Clinicians practicing across general dermatology, as described on the skin conditions overview reference page, encounter these presentations regardless of subspecialty designation.

Core Mechanics or Structure

Melanocytes — the cells responsible for producing melanin — exist at approximately equal density across all human skin tones. The structural differences arise not in melanocyte number but in melanin production volume, melanin type distribution (eumelanin vs. pheomelanin), melanosome size, and the rate of melanosome transfer to surrounding keratinocytes.

In individuals with Fitzpatrick Types IV–VI:

• Melanosomes are larger and distributed as single units within keratinocytes, rather than in the clustered, membrane-bound groupings seen in lighter skin types
• Eumelanin predominates, providing greater photoprotection through broader UV absorption
• The stratum corneum in darker skin tends to have more cell layers and a higher lipid content, contributing to better barrier function in some studies

The Hair Follicle Architecture in skin of color patients — particularly individuals of African descent — includes a curved follicle structure that creates specific susceptibilities to ingrown hairs (pseudofolliculitis), follicular occlusion disorders, and traction injury. This follicle curvature is a documented anatomical factor in conditions including acne keloidalis nuchae and folliculitis decalvans.

Sebaceous gland activity and distribution vary across phototypes, influencing acne morphology. Research published in the Journal of the American Academy of Dermatology has documented that acne in skin of color patients disproportionately results in PIH, which can persist for months to years and represents a primary treatment concern independent of the primary acne lesions themselves.

Causal Relationships or Drivers

The clinical differences in skin of color dermatology are driven by a convergence of biological, historical, and structural factors.

Biological drivers include the melanin axis described above, the heightened inflammatory response that produces PIH following almost any epidermal insult, and the greater fibroblast activity that increases keloid and hypertrophic scar risk. PIH occurs when inflammation triggers excess melanin deposition in the epidermis or dermis; dermal PIH (melanophages in the dermis) is significantly harder to treat than epidermal PIH.

Historical drivers relate to the composition of clinical research cohorts and the development of diagnostic imaging tools. For decades, dermatology atlases, medical school curricula, and dermoscopy training resources predominantly depicted disease presentations on lighter skin. A 2018 analysis published in the Journal of the American Academy of Dermatology found that skin of color represented fewer than 5% of images in major dermatology textbooks (JAAD 2018 study). This training gap directly affects diagnostic recognition: erythema (redness), a cardinal sign of inflammation, is masked or substantially altered in darker skin tones, making conditions like rosacea, contact dermatitis, and cellulitis harder to identify visually.

Structural drivers within the US healthcare system include differential access to board-certified dermatologists, lower rates of skin cancer screening in populations perceived to be at lower risk, and underrepresentation of skin of color patients in clinical trials for dermatological therapeutics. The FDA's 2020 Action Plan for Racial Equity in Clinical Trials acknowledged underrepresentation as a systemic gap affecting drug approval data applicability.

The broader regulatory context for dermatology in the US shapes how these systemic factors intersect with clinical practice standards, board certification expectations, and insurance coverage policies.

Classification Boundaries

Skin of color dermatology overlaps with and is distinct from adjacent clinical categories:

Within scope: Conditions where pigment biology, follicle architecture, or inflammatory response patterns produce clinically meaningful differences in presentation, course, or treatment — PIH, keloids, CCCA, melasma, acne keloidalis nuchae, pseudofolliculitis barbae, DLE with dyspigmentation.

Partially within scope: Conditions that affect all phototypes but require modified diagnostic or treatment approaches in skin of color — atopic dermatitis (where lichenification and follicular accentuation are more prominent than overt erythema), psoriasis (where scaling may appear silvery-gray rather than white, and plaques may leave significant dyspigmentation), and vitiligo (where depigmented macules create higher contrast and psychosocial burden in darker skin tones).

Outside scope: Skin of color dermatology is not a synonym for "conditions unique to Black patients" — it applies to all populations with Fitzpatrick Types III–VI. It also does not encompass the full scope of genetic dermatoses or autoimmune conditions that lack a meaningful melanin-mediated presentation difference.

The Fitzpatrick Scale itself has classification boundaries: it was developed to predict UV response for phototherapy dosing, not as a comprehensive demographic or biological taxonomy. Clinicians and researchers have proposed alternative or complementary tools, including the Individual Typology Angle (ITA) derived from colorimetry and the Roberts Skin Type Classification System (designed specifically for skin of color).

Tradeoffs and Tensions

The subspecialty of skin of color dermatology operates within contested terrain:

Biological specificity vs. racial essentialism: Framing clinical differences in terms of racial categories risks reinforcing non-scientific racial taxonomies. Clinicians and researchers at institutions including Howard University College of Medicine and academic dermatology programs have emphasized that "skin of color" should reference melanin biology and phototype, not race as a social construct.

Sunscreen and photoprotection: A persistent tension exists around photoprotection guidance. Darker skin phototypes have a higher natural SPF equivalent (estimated at SPF 13.4 for Fitzpatrick Type V vs. approximately SPF 3.3 for Type II, per research cited in dermatological literature), which has historically contributed to underemphasis of sun protection in skin of color patients. However, UV exposure still causes DNA damage, contributes to PIH, and drives melanoma risk even in darker phototypes — particularly acral lentiginous melanoma, which is overrepresented in Black and Asian patients.

Cosmetic vs. medical framing: Conditions like melasma and PIH are frequently triaged as cosmetic concerns, affecting insurance coverage and referral patterns, even when they carry significant psychosocial and quality-of-life impacts. The distinction between cosmetic and medical dermatology is discussed further at cosmetic vs. medical dermatology.

Laser and energy-based devices: Devices calibrated for lighter skin (specifically targeting melanin in hair follicles or vascular lesions) carry higher risk of post-treatment dyspigmentation, burns, or scarring in darker phototypes. Selection of appropriate wavelengths — typically Nd:YAG (1064 nm) rather than shorter-wavelength alexandrite or diode lasers — represents a safety-critical decision with direct skin-type dependency.

Common Misconceptions

Misconception: Darker skin does not develop skin cancer.
Correction: While the incidence of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) is lower in darker phototypes, skin cancer does occur across all phototypes. Black patients diagnosed with melanoma have historically presented at later stages and experienced lower 5-year survival rates, a disparity documented in data from the American Cancer Society. This is attributable to lower screening rates and lower clinical suspicion, not biological immunity.

Misconception: PIH is the same as a permanent scar.
Correction: PIH is an acquired dyspigmentation resulting from melanin overproduction following inflammation. Unlike scarring, it does not involve dermal architectural disruption and is, in principle, reversible — though treatment timelines are long and dermal PIH responds more slowly than epidermal PIH.

Misconception: The Fitzpatrick Scale reliably predicts treatment risk across all procedures.
Correction: The Fitzpatrick Scale was validated for UV response prediction. Its predictive validity for laser, chemical peel, or procedural risk is imperfect, and clinicians at academic institutions including the Skin of Color Society have advocated for colorimetric measurement or multi-factor assessment for procedure planning.

Misconception: Rosacea does not occur in skin of color.
Correction: Rosacea is documented across all phototypes. In darker skin, erythema may be subtle or absent as a visible sign, but telangiectasia, papules, and ocular involvement occur. Delayed diagnosis is common due to the erythema masking effect. Reference: National Rosacea Society.

Checklist or Steps (Non-Advisory)

Clinical Assessment Framework for Skin of Color Presentations

1. Document Fitzpatrick phototype at intake using standardized scale — record both self-reported phototype and clinician-assessed phototype where they differ
2. Assess for PIH as a primary or co-primary concern separate from the initiating condition
3. Evaluate scalp and hair for follicular occlusion disorders, traction patterns, and scarring alopecia — conditions covered in alopecia and hair loss
4. Apply adjusted visual criteria for erythema: assess warmth, induration, and patient-reported symptoms when redness is not visually apparent
5. Review procedural device parameters for phototype compatibility before any laser, light-based, or energy-based procedure
6. Document keloid or hypertrophic scar history prior to surgical or biopsy procedures, as documented in guidance on skin biopsy
7. Evaluate psychosocial impact of dyspigmentation, alopecia, or visible skin changes using validated quality-of-life instruments (e.g., Skindex-16, DLQI)
8. Review systemic treatment selection for evidence base in skin of color populations specifically — note whether pivotal trials included Fitzpatrick Type IV–VI participants

Reference Table or Matrix

The comprehensive landscape of US dermatological care — including the training structures, insurance frameworks, and provider networks that shape access to subspecialty skin of color expertise — is documented across the national dermatology authority index and in supporting reference materials.

References

• American Academy of Dermatology (AAD) — Fitzpatrick Scale reference; clinical practice guidelines
• US Census Bureau, 2020 Decennial Census — US population demographic composition
• US Food and Drug Administration (FDA) — Diversity in Clinical Trials — 2020 Action Plan on racial equity in clinical research
• American Cancer Society — Melanoma — Melanoma survival disparity data by race
• National Rosacea Society — Rosacea in skin of color documentation
• Skin of Color Society — Clinical education and research standards in skin of color dermatology
• Journal of the American Academy of Dermatology (JAAD) — Published research on skin of color representation in textbooks and clinical trial populations

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)